Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q3 FY21 results · Oct–Dec 2020
Neuland Laboratories reported revenue from operations of ₹245.39 crore (up 20.4% from Q3 FY20) and net profit of ₹26.74 crore (up 140.6% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 245.39 | 203.84 | +20.4% | 241.39 | +1.7% |
| Other income | 0.20 | 1.02 | −80.9% | 0.61 | −67.8% |
| Total income | 245.59 | 204.87 | +19.9% | 242.00 | +1.5% |
| Profit before tax | 31.95 | 15.67 | +103.9% | 28.69 | +11.4% |
| Net profit for the period | 26.74 | 11.11 | +140.6% | 21.44 | +24.7% |
| EPS, basic (₹) | 20.84 | 8.66 | +140.6% | 16.71 | +24.7% |
| Net margin (%) | 10.9 | 5.5 | 8.9 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 245.39 | 203.62 | +20.5% | 241.39 | +1.7% |
| Other income | 0.20 | 1.02 | −80.9% | 0.61 | −67.8% |
| Total income | 245.59 | 204.64 | +20.0% | 242.00 | +1.5% |
| Profit before tax | 31.86 | 15.57 | +104.6% | 28.58 | +11.5% |
| Net profit for the period | 26.67 | 11.04 | +141.5% | 21.34 | +25.0% |
| EPS, basic (₹) | 20.79 | 8.61 | +141.5% | 16.63 | +25.0% |
| Net margin (%) | 10.9 | 5.4 | 8.8 |
Consolidated
- Filed with BSE
- 02 Feb 2021, 17:05 IST
- Board meeting
- 02 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 02 Feb 2021, 17:05 IST
- Board meeting
- 02 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE